Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

CryoLogyx completes £500k seed funding round

CryoLogyx, a University of Warwick spinout redefining cell technology through cryopreservation, today announced the close of its oversubscribed seed funding round.

18 Mar 2024

New drug candidate designed at the atomic level could help halt emerging SARS-CoV-2 variants

Although COVID-19 has faded from the headlines, SARS-CoV-2 – the coronavirus behind the pandemic – is still rampantly infecting people around the world.

14 Mar 2024

Nuclera appoints Joseph Bertelsen as Chief Commercial Officer

Key appointment to lead global commercial launch of eProtein Discovery platform

From Nuclera 14 Mar 2024

Ricoh and ERS Genomics enter into CRISPR/Cas9 license agreement

...

From ERS Genomics 13 Mar 2024

New custom-designed proteins can efficiently reach intramembrane targets

Hitting targets embedded within the cell membrane has long been difficult for drug developers due to the membrane's challenging biochemical properties. Now, Scripps Research chemists have demonstrated new custom-designed proteins that can efficiently reach these "intramembrane" targets.

13 Mar 2024

UH College of Pharmacy secures CPRIT funding to fight familial adenomatous polyposis

The University of Houston College of Pharmacy is included in a $68.5 million funding package from the Cancer Prevention and Research Institute of Texas (CPRIT).

11 Mar 2024

Scripps Research tests wearable devices as relief for long COVID symptoms

Scientists at the Scripps Research Digital Trials Center have partnered with the health technology company CareEvolution to launch a remote study that will investigate whether wrist-worn devices, such as activity trackers and smartwatches, can help people with long COVID manage and reduce the severity of their symptoms.

11 Mar 2024

Metrion Biosciences strengthens team with three key appointments

Clare Rutty promoted to CFO, Sue Peffer appointed Head of Marketing, Leanne Clarke appointed HR Officer.

From Metrion Biosciences Limited 11 Mar 2024

Ubiquigent enters agreement with Astellas subsidiary, Nanna Therapeutics

Agreement leverages Ubiquigent’s DUB-focused drug discovery platform to support the development of novel therapeutic candidates for multiple disease targets selected by Nanna Therapeutics.

From Ubiquigent Limited 11 Mar 2024

MGI Enters Strategic Partnership with Prepaire Labs to Advance Drug Discovery and Precision Medicine

MGI, a company committed to building core tools and technology to lead life science, today announced its collaboration with Prepaire Labs at MEDLAB Middle East 2024 to further empower precision medicine.

From MGI 6 Mar 2024

Deciphering the role of GPCRs in obesity pathology for drug development

Announcing a new publication for Acta Materia Medica journal. G protein-coupled receptors (GPCRs) are important, potential drug targets for the treatment of metabolic disorders, such as obesity.

5 Mar 2024

Scripps Research scientists uncover plausible pathway for protocell formation

Roughly 4 billion years ago, Earth was developing conditions suitable for life. Origin-of-life scientists often wonder if the type of chemistry found on the early Earth was similar to what life requires today.

29 Feb 2024

UB research may offer a more streamlined approach to developing cancer drugs

Drug discovery can be a frustrating process of trial and error.

28 Feb 2024

Bio-Hermes data reveals strong correlation between blood biomarkers and Alzheimer's amyloid plaques

The Global Alzheimer's Platform Foundation, (GAP) is releasing the first results from the Bio-Hermes-001 Study.

28 Feb 2024

Novel "Tissue-in-a-CUBE" model mimics blood-brain barrier for drug testing

A research team at the RIKEN Center for Biosystems Dynamics Research (BDR) in Japan has succeeded in establishing a model of the blood-brain barrier using modularized tissue derived from human cells.

28 Feb 2024

ChatGPT aids in discovering potential Alzheimer’s treatments through drug repurposing

ChatGPT-4 to identify drug repurposing candidates against Alzheimer’s disease (AD).

28 Feb 2024

FB1006: AI-discovered drug advances to clinical trials for ALS treatment

Amyotrophic Lateral Sclerosis (ALS) is a fatal type of motor neuron disease characterized by progressive degeneration of nerve cells in the spinal cord and brain, resulting in muscle weakness and paralysis that can include the inability to walk and speak, or even swallow and breathe.

27 Feb 2024